CTLA4 and melanoma: For example, several patients with renal cancer and malignant melanoma who showed statistically significant differences in the univariate analysis received IFN as postoperative treatment, and CTLA-4 inhibitors and ICI combination therapy were administered more frequently to patients with malignant melanoma.